Vontobel Holding
VERV

Vontobel Holding’s Verve Therapeutics VERV Stock Holding History

Vontobel Holding’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,000
Closed -$144K – 1159
2023
Q1 		$144K Hold
10,000
– – ﹤0.01% 1008
2022
Q4 		$194K Hold
10,000
– – ﹤0.01% 1000
2022
Q3 		$344K Buy
+10,000
New +$319K ﹤0.01% 822

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vontobel Holding's VERV Position: Q2 2023 in Review

Vontobel Holding sold out of Verve Therapeutics (VERV) in Q2 2023, closing a stake of 10,000 shares — an estimated $144K sold.

Vontobel Holding first reported a position in VERV in Q3 2022 and held it in 3 quarters. The position peaked at $344K in Q3 2022. 121 funds tracked by Wall St. Rank hold VERV as of Q2 2023.

  • Vontobel Holding reported no remaining Verve Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Vontobel Holding sold 10,000 Verve Therapeutics shares in Q2 2023, an estimated $144K.
  • Vontobel Holding first reported a position in Verve Therapeutics in Q3 2022 and held it in 3 quarters.
  • Vontobel Holding's Verve Therapeutics position peaked at $344K in Q3 2022.
  • 121 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2023.

Based on Vontobel Holding's 13F filing for Q2 2023, filed 24 Jul 2023.